TLR9

Across TCGA pan-cancer cohorts, TLR9 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TLR9 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher TLR9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TLR9 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

MESO, LUAD, and BRCA are the cancer types where TLR9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.077	0.580	<.001	42	view →
LUAD	DFS	Median	All	0.294	0.669	<.001	18	view →
BRCA	OS	Median	III,IV	0.313	0.834	.004	12	view →
HNSC	DFS	Median	III,IV	0.204	0.682	.004	6	view →
STAD	OS	Median	II,III,IV	0.153	0.566	.013	6	view →
UCEC	DFS	Median	II,III,IV	0.915	0.441	.045	4	view →
SKCM	DFS	Median	II,III,IV	0.457	0.208	.032	2	view →
READ	OS	Median	II,III,IV	0.773	0.919	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TLR9–MESO (OS)

Open the MESO breakdown →